The Australian Best Places to work 2025 as unveiled in the July 17 edition of The Australian newspaper publication, highlights organisations that have mastered the art of employee engagement, creating workplaces where staff aren’t just productive, but genuinely happy.
Industry sector: Pharmaceutical and medical devices
Number of employees: 11 employees
De Motu Cordis says there is very high in-person collaboration within the company, along with a high level of mutual respect among employees.
“We operate a very open dialogue where a daily catch up shares all key happenings in the business with all team members.
“By nature of being a small team mid-stage start-up, all team members have been exposed to a very broad range of tasks and thus skill acquisition, resulting in them fast tracking their own career development.”
Among organisational initiatives promoting employee engagement are flexible start and finish times, regular celebration of small events, and acknowledgement of milestones. All team members have the opportunity to spend time with and gain insights from a high-profile board of directors, enhancing their learning and development.
Read the full article on Australia’s best places to work 2025 revealed: top ranked companies | The Australian
About DMC
“DMC is a clinical stage pharma company.”
DMC was founded in Brisbane, Australia by Professor John Fraser, an Intensivist and groundbreaking clinician, researcher, and company founder. John is also founder of the Critical Care Research Group and is a co-founder of BIVACOR Pty Ltd. John co-founded the COVID-19 Critical Care Consortium that facilitated collecting over 35 million data points from ICU units worldwide and aided in the development of treatment pathways.
Since inception, DMC has raised over US $21m in Seed rounds primarily in Australia. The majority of funding to date have been secured via the Queensland Business Development Fund, high net worth individuals and Australian family offices. A Series A financing round is planned for H2 2025, which will ideally be anchored by a US based VC.
With more than two decades in pharmaceutical development, Ludovic Bonnet has built a career turning rigorous science into real-world outcomes – from leading Europe’s first generic pMDI approval via in vitro equivalence to advancing over 30 vaccine programmes from concept to validation.
DMC Founder Professor John Fraser AO is among more than 60 leading scientists and three Nobel Laureates calling on the Australian Government to unlock the Medical Research Future Fund.
At the demanding intersection where innovation meets commercial reality, DMC’s Legal Counsel, Sonia Barber stands out as a leader who speaks fluently across law, business, science and global strategy.